Download PDF
Exp Clin Endocrinol Diabetes 2006; 114(7): 348-355
DOI: 10.1055/s-2006-924261
Review Article

J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Incremental Prescription and Drug Costs during the Years Preceding Diabetes Diagnosis in Primary Care Practices in Germany

A. Icks1 , B. Haastert1 , G. Giani1 , W. Rathmann1
  • 1Institute of Biometrics and Epidemiology, German Diabetes Center, Leibniz Institute at the Heinrich Heine University, Düsseldorf, Germany
Further Information

Publication History

Received: May 23, 2005 First decision: October 14, 2005

Accepted: March 13, 2006

Publication Date:
16 August 2006 (online)

Also available at
    Permissions and Reprints

Abstract

Introduction: To evaluate incremental drug prescription costs before diabetes diagnosis in primary care patients in Germany. Material and Methods: Based on 400 primary care practices throughout Germany (Disease Analyzer, IMS Health, Frankfurt, Germany), we selected only patients receiving continuous treatment (age ≥ 40 years) and ascertained drug prescriptions and costs up to 6 years before diabetes was diagnosed. For control, we selected age- and sex-matched nondiabetics (n = 6 294 pairs, age 65.5 ± 10.5 years, 44 % male). We evaluated incremental prescriptions and costs by calculating differences and ratios between patients with and without a diabetes diagnosis. We also evaluated predictors of cost differences using multivariate regression models. The data used for the evaluation was taken from the period 1993 to 2002. Results: The mean number of prescriptions in the year preceding diagnosis in men and women increased 15 % and 19 %, respectively (p < 0.001). Prescription costs were 21 % (men) and 28 % (women) higher in subjects who were destined to receive a diabetes diagnosis (269 and 264 Euros per person) compared to controls (p < 0.001). Incremental prescriptions and costs were already present six years preceding diagnosis. Cardiovascular drugs had the largest impact, accounting for about two-thirds of incremental prescriptions and costs. Women had higher numbers of prescriptions and costs, however, differences and ratios were comparable to men. Incremental costs were higher in patients with private compared to statutory health insurance, and in Western compared to Eastern Germany. Discussion: Numbers of prescriptions and costs in primary care patients with future diabetes diagnosis in Germany were already increased six years before clinical detection, reflecting increased cardiovascular risk even before clinical diabetes diagnosis.

Key words

Type 2 diabetes - primary care - prescription - drug costs

References

  • 1 American Diabetes Association (ADA) . Economic consequences of diabetes mellitus in the U.S. in 1997.  Diabetes Care. 1998;  21 296-309
    PubMedGoogle Scholar
  • 2 Barber J A, Thompson S G. Analysis and interpretation of cost data in randomized controlled trials: review of published studies.  BMJ. 1998;  317 1195-2000
    PubMedGoogle Scholar
  • 3 Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs J B, Bonadonna R C, Muggeo M. Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck Study.  Diabetes. 2004;  53 1782-1789
    CrossrefPubMedGoogle Scholar
  • 4 Brown J B, Nichols G A, Glauber H S, Bakst A W. Type 2 diabetes: incremental medical care costs during the first 8 years after diagnosis.  Diabetes Care. 1999;  22 1116-1124
    PubMedGoogle Scholar
  • 5 D'Agostino R B, Hamman R F, Karter A J, Mykkanen L, Wagenknech L E, Haffner S M. Insulin Resistance Atherosclerosis Study. Cardiovascular disease risk factors predict the development of type 2 diabetes: the insulin resistance atherosclerosis study.  Diabetes Care. 2004;  27 2234-2240
    PubMedGoogle Scholar
  • 6 DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group . Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Re-analysis of European epidemiological data.  BMJ. 1998;  317 371-375
    PubMedGoogle Scholar
  • 7 Dietlein G, Schröder-Bernhardi D. Use of the mediplus patient database in health care research.  Int J Clin Pharmacol Therap. 2002;  40 130-133
    PubMedGoogle Scholar
  • 8 Dukes M NG (ed). Drug Utilization Studies: Methods and Uses. European Series No 45. Copenhagen, Denmark; WHO Regional Office for Europe 1993: 1-4
    Google Scholar
  • 12 Federal Statistic Office (eds) .Health Report for Germany. Stuttgart; Metzler-Poeschel 1998: 379-410
    Google Scholar
  • 9 Grundy S M, Brewer B, Cleeman J I, Smith S C, Lenfant C for the conference participants. Definition of the metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on scientific issues related to definition.  Circulation. 2004;  109 433-438
    CrossrefPubMedGoogle Scholar
  • 10 Gulliford M C, Charlton J, Latinovic R. Increased utilization of primary care 5 years before diagnosis of type 2 diabetes.  Diabetes Care. 2005;  28 47-52
    CrossrefPubMedGoogle Scholar
  • 11 Haffner S M, Stern M P, Hazuda H P, Mitchell B D, Patterson J K. Cardiovascular risk factors in confirmed prediabetic individuals.  JAMA. 1990;  263 2893-2898
    CrossrefPubMedGoogle Scholar
  • 14 Hu F B, Stampfer M J, Haffner S M, Solomon C G, Willett W C, Manson J E. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes.  Diabetes Care. 2002;  25 1129-1134
    CrossrefPubMedGoogle Scholar
  • 15 Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K DECODE Study Group for the. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women.  Arch Int Med. 2004;  164 1066-1076
    CrossrefPubMedGoogle Scholar
  • 16 McPhillips J B, Barrett-Connor E, Wingard D L. Cardiovascular disease risk factors prior to diagnosis of impaired glucose tolerance and non-insulin-dependent diabetes mellitus in a community of older adults.  Am J Epidemiol. 1990;  131 443-453
    PubMedGoogle Scholar
  • 17 Mykkanen L, Kuusisto J, Pyorala K, Laakso M. Cardiovascular disease risk factors as predictors of type 2 diabetes mellitus in elderly subjects.  Diabetologia. 1993;  36 553-559
    PubMedGoogle Scholar
  • 18 Nichols G A, Glauber H S, Brown J B. Type 2 diabetes: incremental medical care costs during the 8 years preceding diagnosis.  Diabetes Care. 2000;  23 1654-1659
    CrossrefPubMedGoogle Scholar
  • 19 OECD Health Data 2002. A software for the comparative analysis of 29 health systems. OECD electronic editions catalogue. 2002
    Google Scholar
  • 20 Rathmann W, Haastert B, Roseman J M, Gries F A, Giani G. Prescription drug use and costs among diabetic patients in primary health care practices in Germany.  Diabetes Care. 1998;  21 389-397
    CrossrefPubMedGoogle Scholar
  • 24 Rathmann W, Haastert B, Icks A, Löwel H, Meisinger C, Holle R. et al . High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA Survey 2000.  Diabetologia. 2003;  46 182-189
    CrossrefPubMedGoogle Scholar
  • 21 Reilly M P, Rader D J. The metabolic syndrome: more than the sum of its parts?.  Circulation. 2003;  108 1546-1551
    CrossrefPubMedGoogle Scholar
  • 22 Selby J V, Ray G T, Zhang D, Colby C J. Excess costs of medical care for patients with diabetes in a managed care population.  Diabetes Care. 1997;  20 1396-1402
    CrossrefPubMedGoogle Scholar
  • 23 The European Group for Study of Insulin Resistance . Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome.  Diabetes Metab. 2002;  28 364-376
    PubMedGoogle Scholar

MD, DrPH, MPH Andrea Icks

German Diabetes Center
Institute of Biometrics and Epidemiology

Auf'm Hennekamp 65

40225 Düsseldorf

Germany

Phone: + 492113382354

Fax: + 49 21 13 38 26 77

Email: icks@ddz.uni-duesseldorf.de

      >